Integra LifeSciences (NASDAQ:IART) Stock Price Down 2.9% - Should You Sell?

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report)'s share price dropped 2.9% on Wednesday . The stock traded as low as $22.04 and last traded at $21.97. Approximately 61,191 shares traded hands during trading, a decline of 94% from the average daily volume of 999,725 shares. The stock had previously closed at $22.62.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley started coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an "underweight" rating and a $20.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $23.00.

Integra LifeSciences Trading Down 1.0 %

The company has a market capitalization of $1.74 billion, a PE ratio of -249.86, a P/E/G ratio of 0.73 and a beta of 1.23. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The firm's 50 day moving average is $23.85 and its 200 day moving average is $22.05.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $442.65 million during the quarter, compared to analysts' expectations of $445.15 million. During the same quarter last year, the business posted $0.89 EPS. The business's revenue was up 11.5% on a year-over-year basis. As a group, equities analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Remove Ads

Institutional Investors Weigh In On Integra LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Sachem Head Capital Management LP purchased a new stake in shares of Integra LifeSciences in the third quarter worth $44,153,000. Soleus Capital Management L.P. bought a new position in Integra LifeSciences in the 4th quarter worth about $28,940,000. Paradigm Capital Management Inc. NY grew its position in Integra LifeSciences by 170.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company's stock valued at $32,457,000 after purchasing an additional 901,600 shares during the last quarter. Lord Abbett & CO. LLC increased its stake in Integra LifeSciences by 86.8% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company's stock valued at $30,210,000 after purchasing an additional 618,773 shares in the last quarter. Finally, Glenmede Trust Co. NA raised its holdings in Integra LifeSciences by 125.9% in the third quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company's stock worth $13,224,000 after buying an additional 405,624 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company's stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.